These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14503948)

  • 1. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
    Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
    Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
    Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.
    Uemura H; Nakagawa Y; Yoshida K; Saga S; Yoshikawa K; Hirao Y; Oosterwijk E
    Br J Cancer; 1999 Oct; 81(4):741-6. PubMed ID: 10574265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
    van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
    Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
    Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
    Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
    Mulders P; Bleumer I; Debruyne F; Oosterwijk E
    Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
    [No Abstract]   [Full Text] [Related]  

  • 8. G250: a carbonic anhydrase IX monoclonal antibody.
    Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
    Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fusion expression of human renal cell carcinoma-associated antigen G250/MN/CA IX in prokaryotic expression system].
    Jiang YD; Zheng SB; Tan WL; Zhao SC; Ren F; Zhang B
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):307-9. PubMed ID: 17425979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
    Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
    PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy.
    Duan Y; Zheng J; Han S; Wu Y; Wang Y; Li D; Kong D; Yu Y
    J Control Release; 2008 Apr; 127(2):173-9. PubMed ID: 18316136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
    Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
    J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.
    Grabmaier K; Vissers JL; De Weijert MC; Oosterwijk-Wakka JC; Van Bokhoven A; Brakenhoff RH; Noessner E; Mulders PA; Merkx G; Figdor CG; Adema GJ; Oosterwijk E
    Int J Cancer; 2000 Mar; 85(6):865-70. PubMed ID: 10709109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of adenovirus to human renal cell carcinoma cells.
    Jongmans W; van den Oudenalder K; Tiemessen DM; Molkenboer J; Willemsen R; Mulders PF; Oosterwijk E
    Urology; 2003 Sep; 62(3):559-65. PubMed ID: 12946777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections.
    Bismar TA; Bianco FJ; Zhang H; Li X; Sarkar FH; Sakr WA; Grignon DJ; Che M
    Pathology; 2003 Dec; 35(6):513-7. PubMed ID: 14660102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
    Kim BR; Yang EK; Kim DY; Kim SH; Moon DC; Lee JH; Kim HJ; Lee JC
    Clin Exp Immunol; 2012 Jan; 167(1):73-83. PubMed ID: 22132887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
    Lamers CH; Langeveld SC; Groot-van Ruijven CM; Debets R; Sleijfer S; Gratama JW
    Cancer Immunol Immunother; 2007 Dec; 56(12):1875-83. PubMed ID: 17479266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of MN/CA IX antigen in carcinogenesis and metastasis of renal cell carcinoma].
    Nakagawa Y; Uemura H; Shimizu K; Cho M; Yoshikawa M; Hirao Y; Yoshikawa K
    Hinyokika Kiyo; 2001 Nov; 47(11):809-14. PubMed ID: 11771176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.